摘要
目的探讨不同部位胃肠间质瘤（GIST）患者的生存情况及手术治疗和药物治疗对患者生存时间的影响。方法回顾性分析2004年1月至2010年12月解放军总医院收治并具有完整病理及随访资料的216例原发GIST患者的临床及随访资料。结果216例患者术后随访1～83（中位22）个月。1、3、5年的生存率分别为90％、87％和82％。GIST位于胃、小肠和胃肠道外患者例数分别为103、45和41例，其5年生存率分别为93％、75％和30％，差异有统计学意义（P〈0．05）；而18例十二指肠GIST和9例直肠GIST随访期间无死亡病例。完整切除加药物（伊马替尼）治疗、完整切除未服用药物、未完整切除加药物治疗及未完整切除未服用药物患者的例数分别为26、155、22和11例．其3年生存率分别为100％、98％、49％和14％，差异有统计学意义（P〈O．05）。结论不同部位的GIST患者预后明显不同．手术完整切除肿瘤和术后服用伊马替尼可改善患者预后。
Objective To analyze the impact of location of gastrointestinal stromal tumor（GIST） on the survival, and the influence of surgical treatment and imatinib therapy on survival. Methods The clinical data of 216 patients with GIST who were admitted to the People＇s Liberation Army Hospital from January 2004 to December 2010 were analyzed retrospectively. Results All the patients were followed up with a median time of 22 months （1 to 83 months）. The 1-, 3-, and 5-year survival rates were 93%, 75% and 30%. The survival rates of 5-year with GIST located in the stomach （ 103 cases）, the small intestine （45 cases） and gastrointestinal outside（41 cases） were 93＇%, 75%, and 30%, respectively, and the differences were statistically significant （P 〈0.05）. There were no deaths in patietns with GIST located in duodenum（18 cases） and rectum（9 cases）. The 5-years survival rates of GIST in the groups of complete excision combined with imatinib, complete resection without imatinib, incomplete resection combined with imatinib, incomplete resection without imatinib were 100%, 98%, 49% and 14% , respectively, and the differences were statistically significant （P 〈0.05）. Conclusions GISTs in different parts of gastrointestinal tract have different survival rates. Radical resection and imatinib can improve the survival rates of patients with GIST.
出处
《中华胃肠外科杂志》
CAS
2012年第3期255-258,共4页
Chinese Journal of Gastrointestinal Surgery
基金
全军“十一五”课题（06MA267）
关键词
胃肠间质瘤
外科手术
伊马替尼
预后
Gastrointestinal stromal tumors
Surgical procedures＇
Imatinib
Prognosis
